After riding out calls for change from Elliot Management earlier in the year, GlaxoSmithKline is facing renewed pressure from a new activist investor, Bluebell Capital Partners.
Another Activist Investor Joins Calls For GSK Leadership Review
Bluebell Capital Has Already Ousted One CEO
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.
More from Business
• By
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
• By
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
More from Scrip
Recent moves in the industry include changes at the top at Novo Nordisk and Takeda, plus Nxera Pharma nabs chief commercial officer from AstraZeneca.
• By
China’s imposed large retaliatory tariffs on US pharmaceuticals on 10 April, but some domestic firms with in-licensed, US-origin assets were already moving to localized manufacturing.
• By
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.